ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

NEUP vs JNJ // OPTIONS IMPLIED MOVE & PUT/CALL SKEW

Neuphoria Therapeutics Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: NEUP 0 — JNJ 8
■ METRIC PARITY
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NEUP VS. JNJ) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC NEUP JNJ SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 67.90% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -11.80% 25.50% -37.30 JNJ /roic <GO>
EV/EBITDA & P/E Valuation — 18.5x — TIE /valuation <GO>
Free Cash Flow Yield 0.47% 2.97% -2.50 JNJ /fcf-yield <GO>
Operating Margin -7.20% 34.70% -41.90 JNJ /operating-margins <GO>
Net Profit Margin -2.40% 28.50% -30.90 JNJ /net-margins <GO>
Revenue Growth (YoY) — 6.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 5.59 -5.39 JNJ /balance-sheet <GO>
Piotroski F-Score Quality 5/9 8/9 -3.00 JNJ /piotroski-score <GO>
Options Implied Move & Put/Call Skew ACTIVE — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 25.4 62.1 -36.67 JNJ /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.08 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 23.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $16.6M $662.49B -$662.48B JNJ /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR NEUP REV JNJ REV NEUP GROSS % JNJ GROSS % NEUP FCF JNJ FCF
FY 2025 $15.6M $94.19B — 67.9% $77.2K $19.70B
FY 2024 $0 $88.82B — 69.1% -$14.7M $19.84B
FY 2023 $0 $85.16B — — -$14.6M $18.96B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NEUP // BETA —
JNJ // BETA 1.08